New Modified Butzler formulation for selective isolation of thermotolerant Campylobacter species from foods and animal feedstuffs is ISO approved and cycloheximide-free
Oxoid has produced a safer alternative to the original Butzler formulation for selective isolation of thermotolerant Campylobacter species from foods and animal feedstuffs from Columbia Blood Agar.
The new Modified Butzler (ISO) freeze-dried Selective Supplement utilises amphoteracin B as an anti-fungal agent in place of cycloheximide, making it safer for laboratory staff to use in culture procedures.
The reformulated supplement achieves the same level of performance as the cycloheximide product, and is ISO-approved.
By utilising a less toxic alternative to cycloheximide, Modified Butzler (ISO) Selective Supplement provides a safer means of suppressing overgrowth by saprophytic fungi and yeasts in Columbia Blood Agar cultures, thus achieving a rating one hazard class lower than the traditional formulation.
In addition to amphotericin B, Modified Butzler (ISO) Selective Supplement includes three other antibiotic agents: cefoperazone, colistin and rifampicin. Cefoperazone inhibits enterobacteriaceae but not enterococci, while colistin is active against a wide range of Gram-positive and Gram-negative organisms and inhibits the growth of organisms such as Pseudomonas species.
Rifampicin is also active against a wide range of Gram-positive and Gram-negative organisms.
Modified Butzler (ISO) Selective Supplement is one of a range of cycloheximide-free media developed by Oxoid to give customers the widest possible choice of traditional formulations and less toxic alternatives.
Both cycloheximide and cycloheximide-free products are available from the company's extensive product range. Customers wishing to order Modified Butzler (ISO) Selective Supplement from Oxoid should quote product code SR214.
